675 related articles for article (PubMed ID: 33875857)
1. Endocrine toxicities of immune checkpoint inhibitors.
Wright JJ; Powers AC; Johnson DB
Nat Rev Endocrinol; 2021 Jul; 17(7):389-399. PubMed ID: 33875857
[TBL] [Abstract][Full Text] [Related]
2. New insight in endocrine-related adverse events associated to immune checkpoint blockade.
Elia G; Ferrari SM; Galdiero MR; Ragusa F; Paparo SR; Ruffilli I; Varricchi G; Fallahi P; Antonelli A
Best Pract Res Clin Endocrinol Metab; 2020 Jan; 34(1):101370. PubMed ID: 31983543
[TBL] [Abstract][Full Text] [Related]
3. Diagnosis and management of toxicities of immune checkpoint inhibitors in hepatocellular carcinoma.
Sangro B; Chan SL; Meyer T; Reig M; El-Khoueiry A; Galle PR
J Hepatol; 2020 Feb; 72(2):320-341. PubMed ID: 31954495
[TBL] [Abstract][Full Text] [Related]
4. Toxicities with Immune Checkpoint Inhibitors: Emerging Priorities From Disproportionality Analysis of the FDA Adverse Event Reporting System.
Raschi E; Mazzarella A; Antonazzo IC; Bendinelli N; Forcesi E; Tuccori M; Moretti U; Poluzzi E; De Ponti F
Target Oncol; 2019 Apr; 14(2):205-221. PubMed ID: 30927173
[TBL] [Abstract][Full Text] [Related]
5. Incidence of Endocrine Dysfunction Following the Use of Different Immune Checkpoint Inhibitor Regimens: A Systematic Review and Meta-analysis.
Barroso-Sousa R; Barry WT; Garrido-Castro AC; Hodi FS; Min L; Krop IE; Tolaney SM
JAMA Oncol; 2018 Feb; 4(2):173-182. PubMed ID: 28973656
[TBL] [Abstract][Full Text] [Related]
6. Endocrine immune-related adverse effects of immune-checkpoint inhibitors.
Trevisani V; Iughetti L; Lucaccioni L; Predieri B
Expert Rev Endocrinol Metab; 2023; 18(5):441-451. PubMed ID: 37682107
[TBL] [Abstract][Full Text] [Related]
7. Endocrine and metabolic adverse effects of immune checkpoint inhibitors: an overview (what endocrinologists should know).
Ruggeri RM; Campennì A; Giuffrida G; Trimboli P; Giovanella L; Trimarchi F; Cannavò S
J Endocrinol Invest; 2019 Jul; 42(7):745-756. PubMed ID: 30471004
[TBL] [Abstract][Full Text] [Related]
8. Endocrine dysfunction induced by immune checkpoint inhibitors: Practical recommendations for diagnosis and clinical management.
Barroso-Sousa R; Ott PA; Hodi FS; Kaiser UB; Tolaney SM; Min L
Cancer; 2018 Mar; 124(6):1111-1121. PubMed ID: 29313945
[TBL] [Abstract][Full Text] [Related]
9. Patterns of toxicity burden for FDA-approved immune checkpoint inhibitors in the United States.
Yang F; Shay C; Abousaud M; Tang C; Li Y; Qin Z; Saba NF; Teng Y
J Exp Clin Cancer Res; 2023 Jan; 42(1):4. PubMed ID: 36600271
[TBL] [Abstract][Full Text] [Related]
10. Thyroid disorders induced by checkpoint inhibitors.
Ferrari SM; Fallahi P; Galetta F; Citi E; Benvenga S; Antonelli A
Rev Endocr Metab Disord; 2018 Dec; 19(4):325-333. PubMed ID: 30242549
[TBL] [Abstract][Full Text] [Related]
11. Endocrine side effects induced by immune checkpoint inhibitors.
Corsello SM; Barnabei A; Marchetti P; De Vecchis L; Salvatori R; Torino F
J Clin Endocrinol Metab; 2013 Apr; 98(4):1361-75. PubMed ID: 23471977
[TBL] [Abstract][Full Text] [Related]
12. Endocrine toxicity of immune checkpoint inhibitors: a real-world study leveraging US Food and Drug Administration adverse events reporting system.
Zhai Y; Ye X; Hu F; Xu J; Guo X; Zhuang Y; He J
J Immunother Cancer; 2019 Nov; 7(1):286. PubMed ID: 31694698
[TBL] [Abstract][Full Text] [Related]
13. The side effects of immune checkpoint inhibitor therapy on the endocrine system.
Goyal I; Pandey MR; Sharma R; Chaudhuri A; Dandona P
Indian J Med Res; 2021 Apr; 154(4):559-570. PubMed ID: 35435341
[TBL] [Abstract][Full Text] [Related]
14. Immune Checkpoint Inhibitors and Endocrine Disorders: A Position Statement from the Korean Endocrine Society.
Kwon H; Roh E; Ahn CH; Kim HK; Ku CR; Jung KY; Lee JH; Kim EH; Suh S; Hong S; Ha J; Moon JS; Kim JH; Kim MK;
Endocrinol Metab (Seoul); 2022 Dec; 37(6):839-850. PubMed ID: 36604955
[TBL] [Abstract][Full Text] [Related]
15. Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune checkpoint inhibitor endocrinopathies and the role of advanced practice providers in the management of immune-mediated toxicities.
Cooksley T; Girotra M; Ginex P; Gordon RA; Anderson R; Blidner A; Choi J; Dougan M; Glezerman I; Gupta D; Johnson D; Shannon VR; Suarez-Almazor M; Rapoport BL
Support Care Cancer; 2020 Dec; 28(12):6175-6181. PubMed ID: 32856213
[TBL] [Abstract][Full Text] [Related]
16. Clinical diagnosis and treatment of immune checkpoint inhibitors-related endocrine dysfunction.
Duan L; Wang L; Wang H; Si X; Zhang L; Liu X; Li Y; Guo X; Zhou J; Zhu H; Zhang L
Thorac Cancer; 2020 Apr; 11(4):1099-1104. PubMed ID: 32043816
[TBL] [Abstract][Full Text] [Related]
17. Cancer immunotherapy - immune checkpoint blockade and associated endocrinopathies.
Byun DJ; Wolchok JD; Rosenberg LM; Girotra M
Nat Rev Endocrinol; 2017 Apr; 13(4):195-207. PubMed ID: 28106152
[TBL] [Abstract][Full Text] [Related]
18. Endocrine side effects of immune checkpoint inhibitors.
Cardona Z; Sosman JA; Chandra S; Huang W
Front Endocrinol (Lausanne); 2023; 14():1157805. PubMed ID: 37251665
[TBL] [Abstract][Full Text] [Related]
19. Immune checkpoint inhibitor-associated pituitary adverse events: an observational, retrospective, disproportionality study.
Bai X; Chen X; Wu X; Huang Y; Zhuang Y; Chen Y; Feng C; Lin X
J Endocrinol Invest; 2020 Oct; 43(10):1473-1483. PubMed ID: 32239475
[TBL] [Abstract][Full Text] [Related]
20. Immune Checkpoint Inhibitors: Review and Management of Endocrine Adverse Events.
González-Rodríguez E; Rodríguez-Abreu D;
Oncologist; 2016 Jul; 21(7):804-16. PubMed ID: 27306911
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
